Fresh from the biotech pipeline—2018

The FDA approved record numbers of new molecular entities, orphan drugs, small-molecule generics and biosimilars in 2018. Could industry’s regulatory success of the past two years become the new normal?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: 2018 FDA approvals.
Fig. 2: 2018 NME approvals by therapeutic class.
Fig. 3: 2018 NME approvals by company category.
Fig. 4: Biosimilar approvals in the US.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Morrison, C. Fresh from the biotech pipeline—2018. Nat Biotechnol 37, 118–123 (2019). https://doi.org/10.1038/s41587-019-0021-6

Download citation

Further reading